{
    "nct_id": "NCT05585034",
    "official_title": "A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb速808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors",
    "inclusion_criteria": "* Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, triple-negative breast cancer, or colorectal cancer that has progressed on standard therapies\n* Part B: Histologically confirmed advanced/metastatic castration-resistant prostate cancer that is PD1-na誰ve; head and neck squamous cell carcinoma that is PD1-na誰ve or has progressed on prior PD1 therapy; or melanoma that is PD1-na誰ve or has progressed on prior PD1 therapy\n* Measurable disease by RECIST 1.1; subjects with prostate cancer who have evaluable disease according to PCWG3 criteria may enroll\n* Life expectancy > 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects currently receiving other anticancer therapies\n* Any prior treatment with an investigational agent targeting CD28\n* History of a life-threatening adverse event related to prior immunotherapy\n* Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically and clinically stable",
    "miscellaneous_criteria": "Key"
}